$NBIX

AI 分析

生成于 May 11, 2026

AI Score
74/ 100
Hold$NBIX

Neurocrine Biosciences

$NBIXNASDAQHealthcareLarge-Cap

Neurocrine develops treatments for neurological and endocrine disorders including Ingrezza for tardive dyskinesia.

Market Cap
$14.0B
Revenue (TTM)
$2.2B
+18.0%
Net Income (TTM)
$0.5B
+25.0%
EPS (TTM)
$3.60
P/E Ratio
38.0
Dividend Yield
0.0%
52-Week Range
$105-$155
Beta
0.42
Dimension Scores
Fundamental
72
Technical
70
Sentiment
76
Risk / Reward
72
Momentum
74
FundTechSentRiskMome
Financial Health
Profitability
77strong
Growth
77strong
Liquidity
80strong
Solvency
74strong
Efficiency
70strong

Valuation, technical analysis, investment thesis, risk assessment and more for $NBIX

Free · No credit card required

免责声明: AI 生成的分析仅供教育参考,不构成投资建议。请始终咨询合格的理财顾问。

探索更多

用 AI 分析任意股票

获取涵盖基本面、技术面、情绪面、风险评估和投资论点的结构化研究报告——约 60 秒完成。